Clincosm LogoSign in Get a demo

invasive lobular breast carcinoma

Showing 1 - 9 of 9
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Invasive Lobular Breast Carcinoma Trial in Salt Lake City ([18F]Fluoroestradiol (FES) PET/CT)

Recruiting
  • Invasive Lobular Breast Carcinoma
  • [18F]Fluoroestradiol (FES) PET/CT
  • Salt Lake City, Utah
    Huntsman Cancer Institute
Jun 14, 2022

Invasive Lobular Breast Carcinoma, ER+ Breast Cancer, HER2-negative Breast Cancer Trial in Belgium, France (Entrectinib,

Recruiting
  • Invasive Lobular Breast Carcinoma
  • +2 more
  • Brussels, Belgium
  • +9 more
May 4, 2022

Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma Trial in New Brunswick, Salt

Active, not recruiting
  • Inflammatory Breast Cancer
  • +9 more
  • External beam radiation therapy
  • New Brunswick, New Jersey
  • +1 more
Jan 30, 2022

Treating Patients With Stage IV Breast Cancer

Active, not recruiting
  • Central Nervous System Metastases
  • +15 more
  • hyperfractionated radiation therapy
  • +2 more
  • North Chicago, Illinois
    University of Chicago
Dec 6, 2021

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Puerto Rico,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +8 more
  • Birmingham, Alabama
  • +859 more
Jul 19, 2021

Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma Trial in Philadelphia

Completed
Has Results
  • Ductal Breast Carcinoma in Situ
  • +6 more
  • Behavioral dietary intervention
  • +4 more
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
Dec 4, 2019

Predict Neoadjuvant Chemotherapy Response in Breast Cancer

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Radiomic, pathomic, and clinical markers
  • Toronto, Ontario, Canada
    Sunnybrook Health Sciences Centre
Jul 12, 2019

Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma Trial in San

Unknown status
  • Infiltrating Duct and Lobular Carcinoma In Situ
  • +2 more
  • Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
  • San Juan, Puerto Rico
    Hospital Auxilio Mutuo Cancer Center
Jul 12, 2012

Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer Trial in

Withdrawn
  • Ductal Breast Carcinoma in Situ
  • +15 more
  • external beam radiation therapy
  • +2 more
  • Cleveland, Ohio
  • +2 more
Dec 7, 2011